Q1 2024 EPS Estimates for Gilead Sciences, Inc. (NASDAQ:GILD) Decreased by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Zacks Research dropped their Q1 2024 EPS estimates for shares of Gilead Sciences in a report issued on Tuesday, April 23rd. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings of ($1.42) per share for the quarter, down from their prior forecast of $1.38. The consensus estimate for Gilead Sciences’ current full-year earnings is $5.24 per share. Zacks Research also issued estimates for Gilead Sciences’ Q3 2024 earnings at $1.84 EPS, Q4 2024 earnings at $1.87 EPS, FY2024 earnings at $3.69 EPS, Q1 2025 earnings at $1.56 EPS, Q2 2025 earnings at $1.61 EPS, Q4 2025 earnings at $1.95 EPS and FY2025 earnings at $7.24 EPS.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. During the same period in the prior year, the firm earned $1.67 EPS. Gilead Sciences’s quarterly revenue was down 3.7% on a year-over-year basis.

GILD has been the subject of a number of other research reports. Wells Fargo & Company cut their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a research note on Wednesday. StockNews.com cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 19th. Finally, Royal Bank of Canada cut their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 14th. Ten investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $84.57.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $67.08 on Thursday. Gilead Sciences has a 52-week low of $65.90 and a 52-week high of $87.86. The stock has a market capitalization of $83.52 billion, a price-to-earnings ratio of 14.91, a price-to-earnings-growth ratio of 0.96 and a beta of 0.19. The company has a fifty day moving average of $71.56 and a 200-day moving average of $76.39. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43.

Institutional Trading of Gilead Sciences

Several institutional investors have recently bought and sold shares of the company. Capital World Investors grew its position in Gilead Sciences by 2.0% during the 4th quarter. Capital World Investors now owns 83,364,123 shares of the biopharmaceutical company’s stock valued at $6,753,350,000 after purchasing an additional 1,642,736 shares during the last quarter. Capital Research Global Investors grew its position in Gilead Sciences by 3.0% during the 4th quarter. Capital Research Global Investors now owns 59,657,126 shares of the biopharmaceutical company’s stock valued at $4,832,824,000 after purchasing an additional 1,743,418 shares during the last quarter. Wellington Management Group LLP grew its position in Gilead Sciences by 14.4% during the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after purchasing an additional 2,350,550 shares during the last quarter. Morgan Stanley grew its position in Gilead Sciences by 0.9% during the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock valued at $1,267,207,000 after purchasing an additional 158,794 shares during the last quarter. Finally, Norges Bank purchased a new stake in Gilead Sciences during the 4th quarter valued at about $1,301,624,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the transaction, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by company insiders.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.59%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.